Compare SATL & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SATL | CAPR |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | 154 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2011 |
| Metric | SATL | CAPR |
|---|---|---|
| Price | $7.95 | $30.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $5.50 | ★ $44.63 |
| AVG Volume (30 Days) | ★ 7.9M | 968.6K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $88.89 | N/A |
| Revenue Next Year | $56.98 | $3.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.26 | $4.30 |
| 52 Week High | $8.90 | $40.37 |
| Indicator | SATL | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 42.17 |
| Support Level | $3.17 | $26.06 |
| Resistance Level | $8.18 | $30.06 |
| Average True Range (ATR) | 0.75 | 2.12 |
| MACD | 0.06 | -0.53 |
| Stochastic Oscillator | 69.81 | 19.86 |
Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.